-April 5, 2024-BOYDSense, a medical device company developing a platform that makes health monitoring simple and pain free, powered by breath, announces the completion of a 7-million-euro capital increase. BOYDSense thus acquires the means to accelerate the development of its non-invasive glucose monitoring device for people living with diabetes and pre-diabetes. This new step is in line […]

-June 16, 2023-In France, more than 3.9 million persons suffer from diabetes. BOYDSense, the Alpha MOS subsidiary dedicated to medical applications, works on a pain-free device to monitor glucose levels with exhaled breath. Along with Toulouse CHU, a clinical study has been conducted on 130 patients with Type-2 that measured their glucose level by blood analysis and […]

-June 1, 2023-Alpha MOS (FR0013421286 ALNEO), world leader in smell, taste and visual industrial instrument analyzers, announces the on-schedule completion of the 2nd clinical study on the non-invasive breath glucose monitoring device developed by its Medtech subsidiary, BOYDSense. The study, promoted by Toulouse University Hospital (CHU) and launched in late 2021 by the Diabetology, Metabolic Diseases and […]

-May 23, 2023-In the program named “Le Zoom de la rédaction” of Tuesday, May 23rd, the journalist Sophie Bécherel gives the floor to Pierre Sbabo, CEO of Alpha MOS, and Bruno Thuillier, founder of BOYDSense. In this report entitled “Blowing instead of pricking yourself”, the company based in Toulouse explains how its future developments could enable diabetes […]

-February 7, 2023-BOYDSense SAS, subsidiary of Alpha MOS (Euronext Paris, ISIN : FR0013421286 ALNEO), has been selected by a jury from the National Union of the Medical Technology Industry (SNITEM) in ordert o participate to the 8th edition of the start-ups day, organized on April 4th at la Cité des Sciences. This event brings together all start-ups […]

-December 12, 2022-BOYDSense SAS, subsidiary of Alpha MOS (Euronext Paris, ISIN: FR0013421286 ALNEO), announces that they have been recognized and awarded in the category “diabetes devices” from the DCB Innovation Challenge 2022. Held every year, the DCB Open Innovation Challenge aims at fostering new initiatives and innovative projects in the domain of diabetes management.BOYDSense breath-based glucose monitoring […]

-September 12, 2019-Boston, Mass. – September 12, 2019 – The RESI Innovation Challenge showcased 38 emerging startups in the biotech, medtech, diagnostics and digital health fields.  All the competitors brought novel, exciting discoveries to the technology showcase […]